Comment on “Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial”

Before the approval of durvalumab, the frequently recommended treatment for unresectable stage III NSCLC was concurrent platinum-based chemoradiotherapy. Nevertheless, previous studies have revealed that such patients who receive concurrent chemoradiotherapy have poor median progression-free survival and overall survival, and a certain percentage of patients do not tolerate chemoradiotherapy.1,2 We read with interest a recent article in the Journal of Thoracic Oncology by Garassino et al.3 entitled "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial." The authors highlighted that durvalumab has a safety profile similar to concurrent chemoradiotherapy in sequential chemoradiotherapy and an encouraging preliminary efficacy in frailer patients.